



Audit and Review of Nurse-Led Clinic for newly diagnosed HIV+ Patients at the GUIDE Clinic

Farrell, G.; Murphy, S.; Nagle, G. & Clarke, S.



Introduction:

- Clinical Nurse Specialists (CNSs) in the GUIDE Clinic run a weekly Nurse-Led Service for Patients Newly diagnosed HIV+
- HIV+ Patients diagnosed elsewhere but wishing to transfer their care were also facilitated in this Nurse-Led Clinic
- The HPSC reports increasing number year on year of new HIV diagnoses, with 508 new cases of HIV notified in 2016
- This current audit reviews the period August 2016-August 2017

Methods, Aims & Objectives

- **Method:** Retrospective data collection from Electronic Patient Record (EPR) and Excel descriptive analysis
- **Aim:** to ensure local and international recommendations are maintained for the newly diagnosed HIV+ patient
- **Objectives:** to evaluate the implementation of local and international policy and guidelines

BHIVA & EACS Guidelines for Newly Diagnosed HIV+ Patients



- Medical Hx incl family Hx, meds, co-morbidities, vaccination
- Psychosocial – lifestyle, employment, morbidity, partner
- Sexual and Reproductive Health – sexual Hx, safer sex, disclosure, conception
- Virology – HIV confirmation, VL, genotypic resistance test
- Immunology – CD4, HLA B5701
- Co-infections – STIs, syphilis, Hepatitis screen
- TB – CXR, +/- Mantoux, IGRA
- Others – MMR, VZV, toxo, CMV
- FBC, G6PD, lipids, RP, LP, BP, Vit D, glucose
- Obs, BMI, ECG, urinalysis, FRAX, Framingham, cervical cytology

Results:


- Total new HIV diagnoses registered to GUIDE August 2016 to August 2017 was 287
- 162 (56%) were seen in the NPC
- **82 were new HIV diagnoses**
- **80 were previously diagnosed but transferring care and new to GUIDE**

Demographics:


	New Diagnoses (N=82)	Transfers (N=80)
Sex:	74 (90%) Male 8 (10%) Female	76 (94%) Male 5 (6%) Female
Mean Age:	36 Range 21-67	36 Range: 24-61
Acquisition Risk:	62 (75%) MSM 17 (21%) Hetro 3 (4%) IDU	58 (73%) MSM 19 (23%) Hetro 2 (3%) IDU 1 (1%) Blood
Time from Referral to Appt	54 (66%) seen within 2 weeks	53 (66%) seen within 2 weeks
Still engaged with GUIDE?	74 (>90%)	71 (89%)

Referral Source and Country of Origin:

Referral Source:



Geographical Origin:



(N=162)

CD4 and HIV Viral Load (VL)- New HIV diagnosis only




- N= 82
- CD4 Median 315 (Range 2-935)
- 39 (48%) CD4 ranging >351
- 28 (34%) CD4 ranging 51 – 350
- **15 (18%) Patients had CD4 <50**
 - **9 of these diagnosed with OI (7 referred from other Hospital)**
- VL Range: ND – 2,832,776 copies/ml
 - 25 (30%) VL >100,000 copies/ml

New Diagnoses and Transfers

	New Diagnosis (N=82)	Transfers (N=80)
Cd4 >350	39 (48%)	64 (80%)
<350	43 (52%)	16 (20%)
OI	13 (16%)	2 (2.5%) (PCP)
VL		92 (77%) were virally suppressed (68 (84%) on HAART)


Opportunistic Infections and Co-Morbidities

Opportunistic Infection at the time of Diagnosis in 15 (18%) Patients



(N=82)


Co-morbidities seen in 70 (43%)
>1 co-morbidity in 18 (11%)



(N=162)

Testing Behaviour, Partner testing, Chem Sex and STIs


- 139 (86%) previously had a HIV test
- 43 had regular partners
 - 38 (88%) were HIV tested
- 18 (11%) engaged in Chem Sex
 - 1 RIP - G
- 148 (91%) had STI screen
 - 21 (14%) +ve STI screen
 - 5 (3%) >1 STI



Medical Reviews +/- Hospital Admission

- 33 (20%) had medical review
 - Indications for medical r/v - rash, confusion, candida, neuro-syphilis review, breast lump, tachycardia
- 8 (5%) required Hospital admission*

Reason for Admission



■ PCP ■ Cardiovascular Disease ■ Anaemia ■ CMV ■ DLBCL ■ OD

*Within 1/12 of review in NPC

Hepatitis Screening, Baseline Serology and Vaccination


- 161 (99.9%) tested for Hep A IgG, HB sAg, cAb and HCV Ab
 - 68 (50%) Hep A non-immune
 - 9 (6%) HBV sAg+
 - 9 (6%) HCV Ab+; 4 (2%) HCV PCR+
- 149 (93%) measles, mumps, rubella, VZV serology
 - 27 (18%) measles non-immune
 - 27 (18%) mumps non-immune
 - 16 (11%) Rubella non-immune
 - 7 (5%) VZV non-immune

Time to Treatment Initiation and HAART Regimens

Newly Diagnosed Patients (N=81*)

- 26 (32%) Commenced HAART at first visit
- 49 (60%) HAART within 1/12
- 3 (4%) deferred
- 3 (4%) already on meds (PEP)

HAART (new diagnoses)




*1 patient excluded as RIP

Genotype testing, HLA B5701, CXRs

- 100% patients with a detectable HIV VL had HIV genotype testing
 - 28 (17%) resistance mutation identified
- 148 (91%) had HLAB5701 testing
- 150 (93%) had baseline CXR performed
 - 10 (7%) had abnormalities – e.g. PCP, effusion, consolidation, bronchitis, lymphoma

Abnormal CXR Findings



MSW and HA Referral

- NPC is multidisciplinary
 - 70 (85%) were offered MSW and 3 (4%) declined
 - 52 were referred to Health Advisor



Patient Feedback:

9 Patients were randomly selected and asked about their experience of the NPC

Positive Feedback:

“found staff to be sensitive and supportive”

“all questions were answered”

“staff should get a payrise”

“everything was explained in English”

“better than Consultants”

Negative Feedback:

“Hard to take in all the information”

“Would be nice to have a leaflet explaining the clinic”

“Don’t like names being called in the clinic “

Discussion:

- High level of compliance to international and local recommendations for the management of new HIV diagnosis
- Recommendations for the initiation of HAART
- High numbers of patients requiring referral for vaccinations
- High level of patient satisfaction but more qualitative work required

Acknowledgements:

- Dr Susan Clarke
- Marian Broderick
- Dr Niamh Lynn
- Gerry Hughes
- All Patients and Staff of the GUIDE Clinic